M

MiMedx Group
D

MDXG

9.19000
USD
0.00
(0.00%)
مفتوح الان
حجم التداول
20,124
الربح لكل سهم
0
العائد الربحي
-
P/E
16
حجم السوق
1,350,435,697
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    A
    -3.140
    (-2.41%)
    127.100 USD
    A
    ALGN
    2.230
    (1.01%)
    223.930 USD
    BSX
    BSX
    -0.590
    (-0.67%)
    87.000 USD
    EW
    EW
    1.620
    (2.45%)
    67.780 USD
    I
    ILMN
    -7.180
    (-5.05%)
    135.110 USD
    I
    IRWD
    0.10500
    (2.56%)
    4.20500 USD
    M
    MTD
    -57.09
    (-4.61%)
    1,180.92 USD
    O
    OSIS
    -1.250
    (-0.82%)
    150.810 USD
    X
    XRAY
    0.385
    (2.15%)
    18.270 USD
    Z
    ZBH
    3.638
    (3.34%)
    112.490 USD
    المزيد
الأخبار

العنوان: MiMedx Group

القطاع: Healthcare
الصناعة: Biotechnology
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.